Brokerages Set Cellebrite DI Ltd. (NASDAQ:CLBT) PT at $16.70

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been given an average rating of “Moderate Buy” by the six research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $16.70.

CLBT has been the subject of several analyst reports. Lake Street Capital lowered their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. JPMorgan Chase & Co. cut their price objective on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 14th. Weiss Ratings cut shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 27th. DA Davidson lowered their target price on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Finally, Needham & Company LLC dropped their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research report on Friday, August 14th.

Insider Buying and Selling

In related news, CFO David Barter sold 41,734 shares of the company’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the sale, the chief financial officer owned 334,219 shares in the company, valued at approximately $5,474,507.22. This represents a 11.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Thomas E. Hogan sold 139,713 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total value of $2,150,183.07. Following the completion of the transaction, the chief executive officer directly owned 790,548 shares in the company, valued at $12,166,533.72. The trade was a 15.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 329,658 shares of company stock valued at $4,970,967 over the last 90 days. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Cellebrite DI

A number of institutional investors and hedge funds have recently modified their holdings of CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after acquiring an additional 850 shares during the last quarter. Advisory Services Network LLC bought a new stake in Cellebrite DI in the third quarter valued at approximately $40,000. CWM LLC raised its holdings in Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after purchasing an additional 889 shares during the period. Elevation Wealth Partners LLC acquired a new stake in Cellebrite DI in the second quarter worth $44,000. Finally, Vestcor Inc bought a new position in shares of Cellebrite DI during the third quarter worth $70,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $11.45 on Monday. Cellebrite DI has a 1-year low of $9.58 and a 1-year high of $19.98. The stock has a market capitalization of $2.86 billion, a P/E ratio of 52.05, a P/E/G ratio of 1.76 and a beta of 1.15. The business has a 50-day moving average price of $14.06 and a two-hundred day moving average price of $13.67.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.